NEXIGN
17.3.2021 09:02:14 CET | Business Wire | Press release
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, and MegaFon, the pan-Russian operator of digital opportunities, have completed the project of unifying billing systems for all 8 MegaFon’s subsidiaries on a single BSS platform. The companies also migrated subscriber data to the new environment with no impact on customers.
The need to go beyond classical telecom services pushed MegaFon to transform the billing core and develop a unified billing system in order to facilitate digital transformation. Among the strategic goals of the project were the reduction of total cost of ownership (TCO) by 20–30% and acceleration of new product launches.
In the course of the project, 7 billing systems utilized in MegaFon were replaced with a single solution. The process was seamless for customers, and the specifics and working arrangements of individual organizations was taken into account during the migration of the B2X segment.
MegaFon achieved the following results:
- Unification of processes for all branch offices;
- Transition from a regional-based to a single shared operation service, which resulted in the increase of its efficiency;
- The product portfolio aligned within all branches of the operator while maintaining the flexibility of local pricing policy;
- Introduction of joint call centers with the same service KPIs and standardized routes for handling calls;
- Improved quality of customer service in the operator’s coverage area;
- Time to market (TTM) for various product categoriesreduced by 2-5 times.
“The collaboration with Nexign has proven to be efficient and successful. We pursued a number of goals traditional for large companies. Aside from optimizing TCO and shortening the time to market for new services, we aimed to improve the customer experience and, as a result, facilitate digital and business transformation. We managed to move all 8 subsidiaries to unified billing processes and switch to a single operation service, which minimized support costs and enabled us to develop an ecosystem for the seamless integration of external partners,” says Sergey Nikiforets, Director of Digital Services at MegaFon PJSC .
Besides the actual implementation of the unified billing system, a number of related projects were completed:
- The integration of the FastTrack methodology designed to automate the update implementation process. Consequently, the team responsible for it decided to spend no more than two weeks on minor changes to the system core — a process that used to last for about a year.
- Development of a microservice factory . Its goal was to accelerate the formation of a partner ecosystem. By using this tool, MegaFon has already launched more than 100 new business projects.
- The introduction of a product catalog that acts as a single point of development and modification of MegaFon’s products and services.
“The joint project with MegaFon is unique for the telecommunications market — both in terms of organized interaction and in terms of results achieved. The Nexign team carried out a comprehensive transformation of the operator’s systems, which enabled MegaFon to not only improve business efficiency and enter a new phase of development, but also to ensure customer loyalty while maintaining a high level of service in all regions. Whereas MegaFon will be able to upgrade the unified billing system to address short-term and long-term business challenges, Nexign’s scalable expertise will benefit telcos looking to develop digital services,” says Igor Gorkov, CEO of Nexign.
About Nexign
Nexign , a part of Intellectual Computer Systems Holding (ICS Holding) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering value-driven, high-performance product solutions since 1992. Headquartered in St. Petersburg, Nexign employs more than 1,800 people. The company has offices and subsidiaries through Russia, the Commonwealth of Independent States, the Middle East, Africa and LATAM.
For more information, please visit the website and follow the latest news from Nexign on Twitter , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005340/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
